“This is another level of validation we are receiving,” says Thomas M. Hitchcock, Ph.D., the Founder and CEO of Xycrobe. “As we are moving forward, it is good to know that the work being done at Xycrobe is resonating with those groups associated with funding Biotech startups, and that this distinction as an SDVG Cool Company will allow us to have the ear of several groups of decision makers that we might not otherwise of had access too during our fundraising journey.”
Xycrobe’s current focus is on inflammatory skin diseases such as acne, psoriasis and dermatitis. These conditions affect over 100 million people in the US alone, and are not effectively addressed by the therapies currently on the market. Xycrobe seeks to address this large need through their development program that utilizes the human microbiome as a means to deliver biotherapeutics.
“We at San Diego Venture Group congratulate Xycrobe Therapeutics on this distinction and believe they will make San Diego proud as they continue on with their successes.” Says Mike Krenn, President of the SDVG.
San Diego Venture Group is a non-profit business association with a mission to support and promote the venture capital and start-up company eco-system in the San Diego region. Its 800 members include venture capitalists, entrepreneurs, experienced executives, and professionals who support them.
ABOUT XYCROBE THERAPEUTICS, INC.
Xycrobe Therapeutics, Inc. is the developer of an innovative, microbial-delivery-system platform technology that can distribute an array of biotherapeutics directly to target tissues, to substantially improve health and quality-of-life. Leveraging the vast amount of data being generated from human microbiome research, Xycrobe is currently developing novel therapies for a variety of clinical applications. Xycrobe is currently a resident company at Johnson & Johnson Innovation – JLABS (JLABS) San Diego. For more information, please visit http://www.xycrobe.com
- END -
Xycrobe Therapeutics Named a “SDVG Cool Company” for 2016
La Jolla, California, 05/11/16 -
It was announced today, May 11, 2016, that Xycrobe Therapeutics, Inc. has been named one of the San Diego Venture Group's (SDVG) 30 Cool Companies for 2016 and will be prominently featured at the upcoming SDVG Venture Summit held on September 7/8, 2016 which attracts over 600 attendees, including at least 80 venture capitalists. Additionally, the chosen companies will be meeting with over 30 Silicon Valley VC’s on August 11 during a private event.
Copyright © 2017 Xycrobe Therapeutics, Inc. All rights reserved.